The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI)

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.

Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.

The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention.

Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice.

Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study.

Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who completed at least one survey at any time point. The use and adoption of these telehealth services were only assessed among DI SSPs at M4 but were assessed among both DI and RI SSPs at M12.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice.

Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on SSPs who completed at least one survey at any timepoint. The use and adoption of these telehealth services were only assessed among DI SSPs at M4, but were assessed among both DI and RI SSPs at M12.

The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice.

Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.

Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI)

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.

Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. The use and adoption of some telehealth services were only assessed among DI PSPs. Only those participants with data available for the specified analysis at the specified time points were included.

AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability.

Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE.

Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on all SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability.

Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.

Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item [I]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs).

Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.

Analysis was performed on all SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.

Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.

Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.

Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.

In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV & PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence, certain Rows have 0 participants analyzed within each Arm/Group.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on SSPs who completed at least one survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.

This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP. Only those participants with data available for the specified analysis at the specified time points were included.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP. Only those participants with data available for the specified analysis at the specified time points were included.

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.

Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.

In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach.

Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).

The protocol-defined endpoint for this outcome specifically requires data presentation by MSM and TGM, so data here are displayed by those groups. Data for this endpoint was collected from all MSM and TGM across DI and RI arms in alignment with the objective, therefore the analysis by MSM and TGM was not completed within arms but across arms.

In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

As pre-specified in the protocol, this outcome measure was evaluated in the MSM and TGM separately. Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question "Have you taken oral PreP in the last 6 months" and number of PSPs who had not heard of PreP.

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP.

Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. This question was not administered to the RI arm; hence they were not assessed. Only those participants with data available at the specified time points were analyzed.

In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study.

Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on data submitted from SSPs who completed at least one FRAME-IS assessment at any time point and had data available for the specified analysis at the specified time points.

The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on data submitted from SSPs who completed at least one FRAME-IS assessment at any time point and had data available for the specified analysis at the specified time points.

The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on data submitted from SSPs who completed at least one FRAME-IS assessment at any time point and had data available for the specified analysis at the specified time points.

PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ and SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on all PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.

General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.

General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available at the specified time points.

General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE.

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Analysis was performed on the SSPs who were interviewed and had data available at the specified time points.